Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03103919
Other study ID # PD0049
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 16, 2017
Est. completion date January 2, 2018

Study information

Verified date February 2019
Source UCB Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate the benefits of Kinesia-360™ wearable technology in addition to standard clinical practice on improving Parkinson´s disease motor symptoms, Neupro dosing regimen and adherence to Neupro compared with only standard clinical practice.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 2, 2018
Est. primary completion date January 2, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subject is newly prescribed Neupro and is expected to commence Neupro treatment. Historical Neupro treatment is permitted

- Informed Consent form (ICF) is signed and dated by the subject, before any study-related procedures

- Subject is considered reliable and capable of adhering to the protocol, visit schedule, completion of the diary, and using Kinesia devices according to the judgment of the Investigator

- Male or female subject, >=18 years of age at the time of the Screening Visit

- Subject has Parkinson's disease, defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: tremor at rest, rigidity or impairment of postural reflexes, and without any other known or suspected cause of Secondary Parkinsonism

- Subject experiences motor symptoms associated with Parkinson's disease that are not sufficiently controlled by current therapy. The average of the triplicate resting tremor scores and triplicate finger tapping scores from Kinesia-ONE™ (6 scores in total) must be >1.0

Exclusion Criteria:

- Subject is currently participating in any study with an investigational medicinal product or investigational device

- Subject has any medical, neurological or psychiatric condition which, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study

- Subject with Deep Brain Stimulation (DBS) device implant

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Kinesia-ONE™
Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
Kinesia-360™
Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
Drug:
Rotigotine
All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.

Locations

Country Name City State
United States Pd0049 102 Boca Raton Florida
United States Pd0049 106 Commack New York
United States Pd0049 105 Fountain Valley California
United States Pd0049 107 Greenville South Carolina
United States Pd0049 109 Houston Texas
United States Pd0049 103 Kansas City Kansas
United States Pd0049 104 Tulsa Oklahoma
United States Pd0049 108 Winfield Illinois

Sponsors (1)

Lead Sponsor Collaborator
UCB Biopharma S.P.R.L.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline to Visit 2 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Motor Score UPDRS Part III has 27 items assessing motor skills including facial expression and speech, tremors, rigidity, posture, gait, and bradykinesia. Each of the 27 items in the UPDRS part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The motor score ranges from 0 to 108, where the maximum score indicates the worse condition. A negative value in change in Unified Parkinson's Disease Rating Scale indicates improvement, whereas a positive value indicates worsening of disease. Baseline (Visit 1/Week 1) to Visit 2 (Week 12/ 3 months after start of treatment with Neupro)
Primary Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Finger Tapping Speed Score Kinesia-ONE™ measures were averaged from triplicate repeated assessments at a measurement point. Kinesia-ONE scores ranged from 0 to 4 (where 0 is normal and 4 represents severe abnormalities), with negative change from Baseline scores indicating improvement in disease symptoms. Baseline (Visit 1/Week 1) to Visit 2 (Week 12)
Primary Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Rest Tremor Score Kinesia-ONE™ measures were averaged from triplicate repeated assessments at a measurement point. Kinesia-ONE scores ranged from 0 to 4 (where 0 is normal and 4 represents severe abnormalities), with negative change from Baseline scores indicating improvement in disease symptoms. Baseline (Visit 1/Week 1) to Visit 2 (Week 12)
Primary Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Averaged Finger Tapping Speed and Resting Tremor Scores Kinesia-ONE™ measures were averaged from triplicate repeated assessments at a measurement point. The finger tapping speed scores and resting tremor scores were averaged and provided as one score ranging from 0 to 4 (where 0 is normal and 4 represents severe abnormalities), with negative change from Baseline scores indicating improvement in disease symptoms. Baseline (Visit 1/Week 1) to Visit 2 (Week 12)
Primary Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Postural Tremor Score Kinesia-ONE™ measures were averaged from triplicate repeated assessments at a measurement point. Kinesia-ONE scores ranged from 0 to 4 (where 0 is normal and 4 represents severe abnormalities), with negative change from Baseline scores indicating improvement in disease symptoms. Baseline (Visit 1/Week 1) to Visit 2 (Week 12)
Primary Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Finger Tapping Amplitude Score Kinesia-ONE™ measures were averaged from triplicate repeated assessments at a measurement point. Kinesia-ONE scores ranged from 0 to 4 (where 0 is normal and 4 represents severe abnormalities), with negative change from Baseline scores indicating improvement in disease symptoms. Baseline (Visit 1/Week 1) to Visit 2 (Week 12)
Primary Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Hand Grasp Speed Score Kinesia-ONE™ measures were averaged from triplicate repeated assessments at a measurement point. Kinesia-ONE scores ranged from 0 to 4 (where 0 is normal and 4 represents severe abnormalities), with negative change from Baseline scores indicating improvement in disease symptoms. Baseline (Visit 1/Week 1) to Visit 2 (Week 12)
Primary Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Hand Grasp Amplitude Score Kinesia-ONE™ measures were averaged from triplicate repeated assessments at a measurement point. Kinesia-ONE scores ranged from 0 to 4 (where 0 is normal and 4 represents severe abnormalities), with negative change from Baseline scores indicating improvement in disease symptoms. Baseline (Visit 1/Week 1) to Visit 2 (Week 12)
Primary Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Rapid Alternating Movement Speed Score Kinesia-ONE™ measures were averaged from triplicate repeated assessments at a measurement point. Kinesia-ONE scores ranged from 0 to 4 (where 0 is normal and 4 represents severe abnormalities), with negative change from Baseline scores indicating improvement in disease symptoms. Baseline (Visit 1/Week 1) to Visit 2 (Week 12)
Primary Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Rapid Alternating Amplitude Score Kinesia-ONE™ measures were averaged from triplicate repeated assessments at a measurement point. Kinesia-ONE scores ranged from 0 to 4 (where 0 is normal and 4 represents severe abnormalities), with negative change from Baseline scores indicating improvement in disease symptoms. Baseline (Visit 1/Week 1) to Visit 2 (Week 12)
Primary Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Dyskinesia Score Kinesia-ONE™ measures were averaged from triplicate repeated assessments at a measurement point. Kinesia-ONE scores ranged from 0 to 4 (where 0 is normal and 4 represents severe abnormalities), with negative change from Baseline scores indicating improvement in disease symptoms. Baseline (Visit 1/Week 1) to Visit 2 (Week 12)
Primary Neupro Dose Per 24h at Visit 2 (Week 12) Daily dose of study medication taken at respective visit. Visit 2 (Week 12)
Primary Number of Neupro Dose Changes During the Study Dose adjustments during study are performed per standard of care. Visit 1 (Week 1) to Visit 2 (Week 12)
Primary Number of Subjects Who Discontinued the Treatment With Neupro During the Course of the Study Number of subjects who discontinued Neupro Treatment were recorded. Visit 1 (Week 1) to Visit 2 (Week 12)
Secondary Number of Subjects With Any Adverse Events During the Course of the Study An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Visit 1 (Week 1) to Visit 2 (Week 12)
See also
  Status Clinical Trial Phase
Completed NCT01736891 - Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations Phase 3
Recruiting NCT03866603 - Rostock International Parkinson's Disease Study (ROPAD)
Completed NCT00902941 - Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline Phase 4
Recruiting NCT01650623 - Gait Training With Executive Functions Tasks in Subjects With Parkinson´s Disease: A Randomised Controlled Trial N/A
Recruiting NCT01650610 - Gait Training With Executive Functions Tasks in Subjects With Parkinson´s Disease: A Study Protocol N/A
Recruiting NCT02578849 - Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia N/A
Completed NCT01038310 - Prognostic Value of FP-CIT-SPECT in Parkinson´s Disease
Completed NCT01003535 - Quantification of Cerebral Cholinergic Function in Parkinson´s Disease by Means of Nuclear Medicine Methods Phase 1
Terminated NCT00562198 - PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding Phase 2
Completed NCT01580787 - Functional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual Environment N/A
Completed NCT00964652 - Treadmill Training With Additional Body Load: Effects on Gait of Subjects With Parkinson´s Disease N/A
Completed NCT01960985 - Balance Training in Parkinson's Disease Using Cues Phase 3
Completed NCT01391741 - The Effect of High-Volume Walking With Visual Cues (VC) in Parkinson´s Disease (PD) Phase 3